The objective of this review is, therefore, to analyze how NRF2 contributes mechanistically to the invasive (T) and metastatic (M) components of tumor progression and to evaluate how pharmacological modulation of this pathway (through direct inhibitors, activators, or metabolic reprogramming) could be exploited to interfere with these stages of cancer evolution. The gene discussed is NFE2L2; the disease is cancer.